High affinity antibodies against HMGB1 and methods of use thereof

US8129130B2 · kind B2 · utility

Assignees

• The Feinstein Institutes for Medical Research · US
• MedImmune Limited · US

Inventors

• Herren Wu · Boyds, US
• Changshou Gao · Potomac, US
• Ling-Ling An · Boyds, US
• Peter Kiener · Potomac, US
• Su-Yau Mao · Gaithersburg, US
• Anthony Coyle · Washington, US
• Jane Tian · North Potomac, US
• Theresa O'Keefe · Waltham, US
• Shixin Qin · Lexington, US

Key dates

• Filing date: Mar 18, 2011
• Grant date: Mar 6, 2012
• Expiry date: Mar 18, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.